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METHODS AND APPARATUS FOR IN VIVO
IDENTIFICATION AND
CHARACTERIZATION OF VULNERABLE

that of infarction, in patients With unstable angina. Addi

ATHEROSCLEROTIC PLAQUES

(Burke A P, Farb A, Malcom G T, Liang Y-H, Smialek J,
Virmani R, Coronary risk factors and plaque morphology in

This application is a continuation (and claims the bene?t
of priority under 35 USC 120) of US. application Ser. No.

men With coronary disease Who died suddenly, N Engl J
Med 1997; 336:1276—82). These have been termed sites of
erosion, and it is estimated that they are responsible for

tional reports noted the occurrence of coronary thrombosis

at sites that do not shoW typical signs of plaque rupture

09/169,621, ?led Oct. 8, 1998 noW abandoned. The disclo

approximately 30% of coronary thrombi, With plaque rup

sure of the prior application is considered part of (and

incorporated by reference in) the disclosure of this applica

10

tion.

caps, both ruptured and non-ruptured, as incidental ?ndings
in patients dying of other coronary lesions, or non-cardiac

FIELD OF THE INVENTION

causes (Falk E, Shah P K, Fuster V, Coronary plaque
disruption, Circ. 1995; 92:657—71). It has also been
observed that approximately 80% of patients dying suddenly
had such lesions in addition to their culprit lesions (Farb A,
Burke A P, Tang A L et al, Coronary plaque erosion Without

The present invention relates to the ?eld of atherosclerosis
intervention. More speci?cally, the invention relates to near
infrared imaging for in vivo identi?cation and characteriZa

tion of tissue including vulnerable atherosclerotic plaques.

rupture into a lipid core: A frequent cause of coronary

BACKGROUND OF THE INVENTION
20

Over the past tWo decades, valuable studies have been
conducted using neW intracoronary technologies to charac
teriZe coronary lesions in living patients. These neW tech

thrombosis in sudden coronary death, Circulation 1996;

93:1354—63). Although many post-mortem studies have
yielded valuable information, there are several important

nologies include angioscopy, ultrasound, and atherectomy.
Studies based upon these approaches have further added to

ture accounting for the remainder. There is a frequent
occurrence in these studies of lipid-rich plaques With thin

25

the knoWledge gained from post-mortem studies. While
much has been learned during post-mortem studies, by

limitations to their use. Because of possible selection bias,
the ?ndings derived from autopsy studies can be generaliZed
With certainty only to those Who die of acute coronary

syndromes. It is quite possible that the prevalence, nature,
and degree of plaque disruption and/or associated thrombo
sis of culprit lesions, is different in those surviving the

de?nition, these investigations cannot provide prospective
data. Furthermore, the procedures used in living patients,

disease. Results from autopsy studies suggest nonetheless

cannot usually provide detailed information on the chemical
composition of the diseased tissue. A signi?cant amount of
relevant information, hoWever, has been derived over the
years through various studies on coronary lesions.
The characteriZation of lesions causing acute coronary

30

syndromes has been advanced signi?cantly by post-mortem

35

that most acute lesions arise from a plaque that includes a

lipid pool, a thin cap, and macrophage in?ltration. While

prospective studies have been limited, these histologic fea
tures may be considered to represent a “vulnerable plaque”,

a term ?rst de?ned by Muller et al (Muller J E et al, Triggers,
Acute Risk Factors and Vulnerable Plaques: The Lexicon of

observations. It Was earlier observed that in human autopsy

a NeW Frontier, JACC 1994; 23(3) 809—13). This type of

specimens of thrombosed coronary arterial segments, the

plaque refers to its functional property of having an

thrombus Was situated at the site of a plaque Where an

increased likelihood of rupture, and may include more than

intimal fracture alloWed the exposure of soft, abscess-like
lipoid material into the lumen of the blood vessel

one histologic type.
40

(Constantinides P, Plaque ?ssures in human coronary
thrombosis, J Atheroscler Res 1966; 6:1—17 (cited refer
ences are incorporated herein by reference)). Subsequently,
it Was shoWn that coronary thrombi responsible for fatal
myocardial infarction Were almost exclusively found at the

acute coronary syndromes. Recently, retrospective analysis
45

site of disrupted plaques (Davies M J, Thomas A C, Throm
bosis and acute coronary artery lesions in sudden cardiac

ischemic death, N Engl J Med 1984; 310:1137—40; Davies
M J, A macro and micro vieW of coronary vascular insult in

ischemic heart disease, Cir 1990; 82(3):38—46; Falk E,
Plaque rupture With severe pre existing stenosis precipitating

The coronary angiogram is considered a primary source
of information for living patients With lesions that cause

50

of coronary angiograms in patients Who subsequently devel
oped unstable angina and myocardial infarction demon
strated that many culprit lesions originate from plaques
previously causing less than 50% stenosis (Ambrose J A,
Tannenbaum M A, Alexopoulos D et al, Angiographic
progression of coronary artery disease and the development
of myocardial infarction, J Am Coll Cardiol 1988; 12, 56-62;
Ambrose J A, Winters S L, Arora R R et al, Angiographic
evolution of coronary artery morphology in unstable angina,

coronary thrombosis: Characteristics of coronary atheroscle

J Am Coll Cardiol 1986; 5,472—8; Nobuyoshi M, Tanaka M,

rotic plaques underlying fatal occlusive thrombi, Br Heart
1983; 50:127—34). The lipid content of human aortic plaques

Nosaka H et al, Progression of coronary atherosclerosis: is
coronary spasm related to progression? J Am Coll Cardiol

rupture or erosion of thrombosed coronary atherosclerotic

1991; 18, 904—10; Little W C, DoWnes T R, Applegate R J,
The underlying coronary lesion in myocardial infarction:
implications for coronary angiography, Clin Cardiol 1991;
14, 868—74). The residual stenosis, after successful throm
bolytic therapy, Was found to be of only moderate severity
in many cases, supporting the concept that occlusive throm
bus frequently develops at coronary sites Without prior
severe stenosis (Kereiakes D J, Topol E J, Sea G, Myocardial

plaques is characteriZed by an in?ammatory process irre

infarction With minimal coronary atherosclerosis in the era

displaying ulceration and thrombosis Was observed to be

55

greater than that of non-disrupted plaques. Similarly, in
patients dying of acute myocardial infarction, previous
research revealed that While culprit lesion morphology in
myocardial infarction is heterogeneous With respect to
plaque architecture and cellular composition (van der WalA

60

C, Becker AE, van der Loos C M, Das P K, Site of intimal

spective of the dominant plaque morphology, Circulation
1994; 89:36—44), the immediate site of plaque rupture is
marked by an in?ammatory process. An incidence of plaque
disruption of about 83% has been also reported, similar to

65

of thrombolytic reperfusion, J Am Coll Cardiol 1991; 17,
304—12; BroWn G G, Gallary C A, Badger R S et al,
Incomplete lysis of thrombus in the moderate underlying
atherosclerotic lesion during intracoronary infusion of strep

US 6,816,743 B2
3

4

tokinase for acute myocardial infarction, Circulation 1986;
73, 653—61). Despite these advances, the use of coronary
angiography to study coronary atherosclerotic lesions in
living patients has severe limitations including its inability

R, Nair R N, Lesnefsky E J, Sheehan H M, Intracoronary
ultrasound imaging: correlation of plaque morphology With
angiography, clinical syndrome, and procedural results in
patients undergoing coronary angioplasty, J Am Coll Cardiol
1993; 21, 35—44; Nissen S E, Gurley J C, Booth D C,
McClure R R, Berk M R, DeMaria A N, Spectrum of

to provide information about the sub-surface features of the

plaque. The relatively loW sensitivity and speci?city of a

intravascular ultrasound ?ndings in atherosclerosis: Wall
morphology and lumen shape in CAD patients, J Am Coll
Cardiol 1991; 93; Nissen S E, Gurley J C, Grines C L, Booth
D C, McClure R, Berk M, Intravascular ultrasound assess
ment of lumen siZe and Wall morphology in normal subjects
and patients With coronary artery disease. Circ. 1991; 84,

plaque’s geometric surface features to predict subsequent
occlusion indicate that other plaque-related characteristics

(i.e., plaque composition), not detectable by angiography,
may be more important in the determination of plaque

vulnerability (Taeymans Y, Theroux P, Lesperance J, Waters
D, Quantitative angiographic morphology of the coronary

1087—99). Unfortunately, the sensitivity and speci?city of

artery lesions at risk of thrombotic occlusion, Circulation

ICUS to identify particular components of a lesion, includ

1992; 85, 78—85).
The development of angioscopic imaging devices for the

ing lipid-rich regions With thin caps, is limited by the
15

coronary arteries also provided a valuable opportunity to
de?ne the surface features of lesions Which cause unstable

resolution of ICUS technology, and its further inability to

identify chemical composition of subject tissue.
The performance of atherectomy procedures further pro

angina and acute coronary syndromes. Angioscopic imaging

vided signi?cant information relating to coronary lesions.

devices Were used percutaneously to obtain a clear vieW,

For example, in a study of atherectomy specimens in living
patients With stable and unstable coronary syndromes
(Moreno P R, Falk E, Palacios I F, NeWell J B, Fuster V,

With magni?cation, of the inner surface of the coronary

lumen in patients undergoing catheteriZation. Normal seg
ments of coronary arteries in living patients Were observed
to be White and smooth, While disrupted atherosclerotic
plaques causing disease Were elevated and, in many cases,

yelloW and/or red in color (MiZuno K, Miyamoto A, Sato

Fallon J T, Macrophage in?ltration in acute coronary syn

dromes: Implications for plaque rupture, Circulation 1994;
90:775—8), it Was shoWn that macrophage-rich areas are
25

more frequently found in patients With unstable angina and

mura K et al, Angioscopic coronary macromorphology in
patients With acute coronary disorders, Lancet 1991; 337,
809—12). Imaging of the site of percutaneous transluminal

unstable atherosclerotic plaques. More recently, macroph

coronary angioplasty (PTCA) also permitted identi?cation

establishing a cell-mediated thrombogenicity in unstable

of the mechanism of abrupt closure (SassoWer M A, Abela
G S, Koch J M et al, Angioscopic evaluation of peri

Cueller J et al, Macrophages, smooth muscle cells and tissue

non-Q Wave myocardial infarction, and are a marker of
ages have been identi?ed as a major source of tissue factor

atherosclerotic plaques (Moreno P R, Bernardi V H, LopeZ

procedural and post-procedural abrupt closure following

factor in unstable angina: Implications for cell-mediated

percutaneous coronary angioplasty, Am Heart J 1993). A

thrombogenicity in acute coronary syndromes, Circulation

study using angioscopy demonstrated that patients With
“glistening yelloW” plaques had a 68% incident rate Within
the subsequent year of unstable angina or myocardial

35

clinical purposes, and it is anticipated that many plaques
causing disease Will not be stenotic, and hence cannot be

infarction, as opposed to a 4% in those Without such lesions

(Uchida et al, Prediction of acute coronary syndromes by
percutaneous coronary angioscopy in patients With stable
angina, Amer Heart J 1995, 130 (2): 195—203). Despite the

sampled by atherectomy performed for clinical indications.
40

Sampling errors may also occur if only the super?cial aspect
of the plaque is retrieved Which obscure anatomic relation
ships With the rest of the plaque.
Other techniques for analyZing coronary lesions have
been also proposed. Recent approaches for identi?cation of

45

vulnerable plaque, for example, include thermography,
ultra-fast CT, magnetic resonance imaging (MRI) and opti
cal coherence tomography (OCT) (BreZinski M E, Tearney

obvious advantages of imaging the interior of a coronary

artery, the angioscope can only generally provide informa
tion about the shape and color of the interior surface of the
blood vessel. The technique also requires a period of coro
nary occlusion and an experienced team for safe perfor
mance. The interpretation of ?ndings With terms such as

“glistening yelloW” are particularly subjective and may
provide inconsistent results.

G J, Bouma B E et al, Optical coherence tomography for

Intracoronary ultrasound devices have been also used to
characteriZe coronary lesions. It is possible to identify
certain characteristics of these lesions beneath their intimal
surface. The ability of intravascular coronary ultrasound
(ICUS) to identify tissue characteristics of lesions has been
established in in vitro studies With histologic correlation

(Tobis J M, Mahon D, Moriuchi M et al, Intravascular
ultrasonic imaging, Tex Heart Inst J 1990; 17, 181—9; Tobis

55

J M, Mallery J, Mahon Dea, Intravascular ultrasound imag

optical biopsy. Circulation 1996; 93:1206—13; BreZinski M
E, Tearney G J, Weissman N J et al, Assessing atheroscle
rotic plaque morphology: Comparison of optical coherence
tomography and high frequency intravascular ultrasound,
Heart 1996; 77:397—403; Toussaint J -F, LaMuraglia GMSJF,
Fuster V, Kantor H L, Magnetic resonance images lipid,
?brous, calci?ed, hemorrhagic, and thrombotic components
of human atherosclerosis in vivo, Circ. 1996; 94:932-8).
Each of these approaches exhibit some relative strengths and
limitations. For example, thermography has not yet been

ing of human coronary arteries in vivo: Analysis of tissue
characteriZations With comparison to in vitro histologic

validated in vivo, and ultrafast CT is an excellent Way to
detect calcium but other ions and compounds are not

specimens, Circ. 1991; 83, 913—26). Fibrous plaques pro
duce bright images With echo-free shadoWing. Plaques With
extracellular lipid or necrotic material displayed minimal

re?ectivity typically appearing in the form of hypoechoic
areas, but differentiation from thrombus is quite often dif
?cult. Such correlation studies have led to Widespread use of

1996; 94:3090—7). There are hoWever several limitations to
the use of atherectomy specimens to study vulnerable coro
nary plaques. The technique is no longer in frequent use for

65

detected. MRI is generally not suited for imaging of the
small, moving coronary arteries, as opposed to the relatively
siZable carotids. OCT can provide images but has not yet
been reported to obtain images through blood. The limita
tions of these techniques for analyZing arterial diseases

the terms “hard” or “soft” to characteriZe lesions based on

preclude their useful and practical application for clinical

these ultrasonic images (Hodgson J M, Reddy K G, Suneja

purposes.

US 6,816,743 B2
6

5
It has been generally observed that atherosclerosis, With

been used trans-arterially on exposed carotid arteries in

out associated thrombosis, is often an innocuous and asymp

living patients undergoing endarterectomy. Images Were

tomatic disease. Many patients With atherosclerosis can be
treated surgically or by drugs With high initial success, and
often have a favorable long-term prognosis. The acute

necrosis With an indium antimonide focal plane array video

obtained of ?brous cap, lipids, thrombus, ulceration and
camera (Dempsey R J, Cassis LA, Davis D G, Lodder R A,
Near-infrared Imaging and Spectroscopy in Stroke
Research: Lipoprotein Distribution and Disease, Ann. NY.
Acad. Sci. 1997; 820:149—69). It has been observed that

manifestation of atherosclerosis, commonly occurring as
myocardial infarction, unstable angina, or sudden death,
usually arises When thrombus develops. These serious
events typically develop at the site of plaque ?ssure or
rupture. A number of studies have demonstrated that plaque

near-IR spectral analysis has chemical imaging ability, and
10

rupture plays a pivotal role in the pathophysiology (the
physiology of abnormal states and the functional changes
that accompany a particular syndrome or disease) of acute
coronary syndromes. Recent research indicates that it is
often not the severity of stenosis (a narroWing or constriction
of the diameter of an artery by plaque volume) that deter

the frequency domain. Biophys J 1991; 167a). Near-IR
15

Raman spectroscopy has been also used recently to quanti

tatively analyZe the lipid component of human atheroscle
rotic plaques (Weinmann et al, Quantitative analysis of

mines a potential outcome. It is more often the type of

stenosis, or the chemical composition of the plaque, and the
extent of collateral groWth Which becomes a determining

factor. The kind of plaque, determined by composition,

further provides useful information and detail relating to
various internal body structures such as muscle, bone, and
arteries (Van de Van M, French T, Fishkin J, Gratton F,
Near-infrared imaging spectroscopy of mammalian tissue in

cholesterol and cholesteryl esters in human atherosclerotic
20

consistency, vulnerability and thrombogenicity, varies

plaques using near-infrared Raman spectroscopy, Athero
sclerosis 1998; 140(1), 81—8) and may provide vibrational
information on chemical structures Without penetration of

greatly from patient to patient, even from plaque to plaque

more than a feW microns of Water or blood. While Raman

in different locations, and there is no simple relation among

spectroscopy may provide some analysis of plaque under
certain test conditions, many technical dif?culties including
its inherent inef?ciency prevent or limit its broad application
in living patients through catheter-based systems. The per

plaque kind, plaque volume or stenosis severity.
Near-IR spectrometry has been performed in a limited

25

number of applications for analyZing and detecting the
presence of knoWn indicators associated With a particular
disease or condition. For example, lipids have been exam
ined With near-IR in vitro and in vivo in gerbil brains

folloWing experimentally induced stroke, and provided the

30

formance of Raman spectroscopy through a catheter is also
believed to be a time-consuming and inherently inef?cient
process that fails to provide accurate quanti?cation of plaque
constituents.

identi?cation of nine different saturated and unsaturated

SUMMARY OF THE INVENTION

fatty acids found in the gerbil brain. The changes in Water
content related to edema and changes in proteins Were also

The present invention provides reliable methods and

monitored non-invasively by near-IR spectrometry in these

apparatus for detecting and analyZing the composition of
vulnerable plaques in living tissue With near-infrared (IR)

studies. Near-IR spectrometry has also been used to analyZe
HDL, LDL, and cholesterol in the blood vessels of rats, and

35

radiation. The invention, in a non-destructive manner, may

has been performed With ?ber-optic probes to determine fat
content in meats commercially (Nagao A, UoZumi J, IWa

provide early detection of vulnerable plaques before the

moto M, YamaZaki M, Determination of fat content in meats

of the procedure used to determine the chemical composi

onset of an acute syndrome. Near-IR spectroscopy, a variant

by near-infrared re?ectance spectroscopy, Chem Abstr 1985;
219697r), and to determine total body lipids in humans
non-invasively (ConWay J, Norris K, BodWell C, A neW
approach for the estimation of body composition: Infrared
interactance, Amer J Clin Nutr 1984; 1123). In addition,

40

near-IR imaging has been used in human stroke patients to
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analyZe atherosclerotic plaque by identifying and locating
oxidiZed lipoprotein spectral signatures. A near-IR imaging
system and parallel vector supercomputer has been used
With a ?ber-optic probe to produce chemical maps of the
intimal surface of living arteries. Spectrometric data col

Another object of the present invention is to provide a
50

When it is realiZed that some of the drugs or devices
prescribed to treat lesions may have serious side effects
55

Which may, in some instances, be avoided altogether. Still
another object of the invention is to provide a method and
apparatus Wherein infrared radiation of a Wavelength range
from about 1400—4100 nm, and more preferably from about
1600—1800 nm, is sequentially focused onto selected arterial
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endothelium. The re?ected or scattered infrared radiation

avoided the matrix factoriZation that generates excess error

in other pattern recognition methods, and permitted analysis

may be then detected and analyZed at high speed in accor
dance With the invention to not only identify vulnerable
plaques, but to also evaluate the progression of disease and

5.5 micrometers and depth resolution of 6.5 micrometers
Were achieved With the system. Controlling the apertures on

?ber-optic probes permitted the three-dimensional relation

effectiveness of treatment.

ships betWeen sample components to be determined. Data

from the ?ber-optic probe con?rmed the injury hypothesis of
lesion formation and the differing roles of HDL and LDL in

cholesterol transport. Additionally, near-IR spectrometry has

method and apparatus speci?cally adapted to identify vul
nerable plaques to thereby alloW physicians to prescribe
appropriate drugs that are more likely to provide effective
treatment. This is a particularly important consideration

quantify the constituents of each voxel in the artery Wall
in a Wavelength space of over 1000 dimensions using feWer
than 100 calibration samples. Asurface feature resolution of

nary arteries of living patients. The small risk to patients
associated With near-IR imaging Will be balanced against the
possible bene?ts of improved risk-strati?cation and effective

therapy.

lected at hundreds of near-IR Wavelengths Were assembled

into color pictures of the lipoprotein and apolipoprotein
composition of early atheromas using a vectoriZed 3-D
cellular automaton-based algorithm that operates in parallel.
The nonparametric mathematics developed to identify and

tion of extraterrestrial rock samples, may identify plaques
With a lipid pool and thin cap in vivo. In accordance With the
invention, this may be performed through a near-IR coro
nary catheter for identifying vulnerable plaques in the coro
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In accordance With the principles of the present invention,
improved near-IR imaging apparatus may be provided for
analyZing vulnerable plaques The apparatus may not be only
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utilized for in vitro analysis, but may also be advantageously
utilized for in vivo analysis. The apparatus may comprise a

parallel at all locations being analyzed. The analysis of the
re?ected light may be also completed simultaneously and in

light source for transmitting simultaneously and in parallel

parallel for all locations being analyzed over the same range
of Wavelengths. As all tissues absorb light at all these

an incident beam of light of a Wavelength range from
approximately 1400 to 4100 nm, and more preferably Within

Wavelengths, With different tissues absorbing only a little

a “Water WindoW” such as from about 1600 to 1800 nm or

more at some Wavelengths than others, this broad band

around 2080 nm. A ?ber-optic probe may be operatively

parallel approach may be useful to reduce the risk of missing
unusual tissue during study. Hence, the analysis may be
more accurate and complete. When identifying peaks for

connected to the light source, and a light directing or
focusing mechanism may be mounted to the distal end of the

probe. The focusing mechanism may comprise a compound
parabolic concentrator (CPC) that may, for example, be
formed from plastic and include a polished aluminum lining.

10

The CPC is similar to those designed for use for solar poWer

concentration. In particular, the CPC may be adapted to
compress the incident beam from the transmitting ?ber-optic
onto a small spot on the tissue surface undergoing analysis.
Additionally, the apparatus may include detectors such as
lead sul?de detectors for detecting the scattered light from
the artery surface or other tissue being analyzed. In an
alternative embodiment, the light directing mechanism com

15

particular lipids and cholesterol Which are knoWn to occur at
certain ranges or Water WindoWs, the analysis may be
modi?ed in accordance With the invention to more readily

detect and identify the existences of vulnerable plaques.
Furthermore, as the focusing of near-IR radiation and analy
sis are performed in parallel, the complete study may still be
completed in a suf?ciently short time span to alloW clinical
utilization as With arterial angiography. In accordance With
a further method of analyzing arterial endothelium in vivo

20

utilizing a ?ber-optic probe, the method may include the
initial step of introducing the probe into an artery of a patient

prises an inverted, substantially conical re?ector developed
from both ellipsoids of rotation and paraboloids of rotation.

pumped KTP/OPO tunable near-IR laser system may be

This re?ector may direct the incident beam from the trans

utilized as a light source for the ?ber-optic catheters and

mitting optic ?ber over the tissue undergoing analysis.
Additionally, light re?ected or scattered by the tissue is

in combination With a coronary catheter. A NdzYAG

25

directed or focused into receiving optic ?bers so as to alloW

for better detection and hence, chemical analysis of the
tissue. The ?ber-optic catheter may also comprise separate
bundles of ?bers to inject light into the vessel Wall at one

location, and detect light scattered through the plaque and

related methods disclosed herein. The BEST algorithm may
be used to construct chemical-composition images of the
intima of the aorta in test subjects in vivo.
It is another object of the invention to provide methods
and apparatus using near-IR spectrometric imaging to non

destructively locate and identify pools of LDL cholesterol
30

Which may serve as an in vivo marker for vulnerable

vessel Wall at another location. The light injection and
detection ports may be placed in contact With the vessel Wall

usually contain a sizable lipid pool containing LDL covered

using a balloon or other device during the measurement and

by a thin ?brous cap. Near-IR imaging spectrometry may be

atherosclerotic plaques. Vulnerable plaques are thought to

therapeutic processes. A portion of the transmitting ?bers

performed as prescribed herein to measure the size and the
may also be directed onto a re?ectance standard at the 35 chemical composition of the ?brous cap and the lipid pool.
catheter tip and returned to a detector module for use in
An accurate measurement of lipoprotein cholesterol is a

absorbance ratios. The apparatus may further include suit

useful ?rst step in the intervention against diseases such as

ably sized catheters and equipment for high speed parallel

atherosclerosis and ischemic stroke, and is important in

analyzing of the spectra re?ected from the tissue, and
producing color images thereof. Such equipment may, for

determining What constitutes a vulnerable plaque in order to
derive an effective means for stabilizing such plaque.
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example, include a computer such as a supercomputer used

Because cholesterol is carried in lipoprotein particles that
differ in size and apolipoprotein composition, this variety of

at the University of Kentucky, and appropriate softWare such

as the copyrighted Bootstrap Error-Adjusted Single-Sample

lipoproteins often make non-destructive differentiation of its
composition dif?cult in the living vessel Wall. As a result,

Technique (BEST) Algorithm softWare program developed
by Robert A. Lodder. Further, the ?ber-optic probe may be
preferably adapted for introduction into a patient to thereby
alloW in vivo analysis of artery Walls, or in particular, lesions

45

nation of plaque lipoprotein composition. HoWever, produc
tion of artifacts is common using in vitro methods and has
lead to confusion in the literature. At present, there is no in
vivo assay for LDL and forms of oxidized LDL (oxLDL) in

Which may characterized as vulnerable plaques. Additional

information relating to these and other applications of the
present invention may be further described in US. Pat. No.

most studies focus on in vitro methodologies for determi
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solid tissue atherosclerotic plaques. More speci?cally, there

5,441,053 (APPARATUS AND METHOD FOR MUL
TIPLE WAVELENGTH ANALYSIS OF TISSUE) Which is

is currently no accurate non-destructive in vivo reference
assay for LDL or apolipoproteins immobilized in the Walls

incorporated by reference herein.

of living human arteries. Chemical analysis of lesions in
vivo Would provide for the kinetic characterization of
atherogenesis Which contribute to the understanding of
lesion formation and groWth. HoWever, the near-IR spec
trometry of plaque in vivo as described herein may thus
facilitate assignment of patients to speci?c neW drug inter
ventions that may affect the course of atherosclerosis (such

A further aspect of the present invention provides various
methods of analyzing arterial lesions With near-IR spectros
copy for the existence of vulnerable plaque characteristics.
The method may include the steps of focusing light on the
tissue to be analyzed, and detecting light re?ected by the
tissue. The light being focused may have a Wavelength
ranging from approximately 1400 to 4100; and more pref

55
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erably 1600 to 1800 nm. The method may further include a

step of analyzing the spectra from the tissue and producing
color images thereof. Advantageously, both the focusing and
analyzing steps may be performed to alloW high speed data
acquisition and analysis. Speci?cally, light having a range of
Wavelengths from 1400 to 4100 nm, and more preferably
from 1600 to 1800 nm, may be simultaneously focused in

as TPA, Which acts to block thrombi, Enlimomab, Which acts
to block granulocyte adhesion to the blood-vessel Wall,

Citicoline, Which reduces free fatty acids, Lubeluzole, Which
interferes With the effects of nitric oxide, Tirilizad, Which
acts as a free-radical scavenger, or bFGF, Which acts on
65

groWth factors) and/or surgical interventions such as bypass
grafts or angioplasty and stents. The basic near-IR imaging
techniques provided herein are based at least in part on the
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principle that many organic molecules absorb light in the

imaging systems provide possible prospective identi?cation

near-IR spectrum in a speci?c manner. This creates unique
re?ectance spectra that can be analyzed to perform a non
destructive chemical analysis of tissue either through a
microscope, or at a distance through a ?ber-optic catheter. A

of vulnerable coronary artery plaques in living patients.
Particular investigations may be conducted in accordance
With the invention: to obtain additional calibration and
blinded validation of near-IR imaging in ex vivo human

autopsy specimens (blocks from aortas and coronary
arteries); to test the ability of catheter-based near-IR imaging
to detect vulnerable aortic plaque in vivo (in rabbits) With
diet-induced atherosclerosis; to perform near-IR catheter
based mapping of coronary artery chemical composition in

NdzYAG-pumped KTP/OPO laser system may be used With
spectrometric catheters for use in analyzing atherosclerosis
and markers of vulnerable plaque. The near-IR spectromet
ric catheter may be thus used for early detection of LDL
uptake in the arterial Wall even before the appearance of

patients undergoing PTCA and/or stenting; and to identify
rapid lesion progression by angiography and clinical events

visible fatty streaks. Another object of the invention there
fore is to provide near-IR laser spectrometric assays of
plaque Which may be performed With cardiac catheters in
vivo to facilitate the assignment of patients to speci?c drug

during subsequent years. When potentially high-risk patients
are identi?ed With near-IR signatures of plaques With lipid
pools and thin caps, for example, they may be subject to a

or surgical interventions that are selected to match their 15
further therapy study to stabiliZe vulnerable plaques.

individual vulnerable plaque characteristics.

Another object of the invention is to thus provide therapeutic
methods and apparatus to stabiliZe plaques that have been
characteriZed as vulnerable by using near-IR therapy to

Other aspects of the invention are directed to the role of

group V secretory phospholipase A2 (sPLA2), an important
enZyme in in?ammatory processes, in the generation of
vulnerable atherosclerotic plaques. Near-IR imaging may be
used to identify predetermined compounds such as sPLA2,
and to survey for neW compounds. For example, lysophos
phatidylcholine (LPC) is a major product of sPLA2 action.

promote ?brosis or thickening of the thin ?brous caps

covering these lipid pools to prevent their rupture or leakage.
The subsequent treatments to be administered may further
include an orally active matrix metalloproteinase inhibitor

Since there are no speci?c antibodies to LPC that could be

used for immunohistochemical studies, its localiZation in
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various regions of plaque may be determined by near-IR
imaging of histologic sections. Moreover, near-IR spectra

vulnerable plaques.
In accordance With another aspect of the invention, it is
further possible to determine the relationship betWeen the
prospective near-IR chemical map of the human coronary
tree, and the rapid progression of coronary lesions as of
one-year later Which may be documented by angiographic

may be obtained for lesions from animal studies overex

pressing sPLA2 activity. These spectra, Which may re?ect a
combination of elements potentially associated With
vulnerability, can be compared With the spectra obtained in
patients at sites proven to be vulnerable by occurrence of
subsequent events. Spectra from the animal studies may thus
identify a compound not yet suspected to be associated With
vulnerability in humans. The role of serum amyloidA(SAA)

and/or autopsy ?ndings. These ?ndings may be provided
from a study involving a relatively large number of patients
35

has been also shoWn to be an important cofactor for sPLA2
activity, and associated With clinical events. Its role may be

patients undergoing near-IR imaging. The overall impor
40

be further recogniZed if sPLA2 is indeed determined to play
a major role in this condition. An sPLA2 inhibitor may be
thus used as ?rst-line therapy for patients found to have a
vulnerable plaque. In any event, the ?nal decision on therapy
in patients Will be made on the basis of the best information
available at the time of treatment. The invention provides an
increased understanding as to the diagnosis, and treatment,
of vulnerable coronary plaques. This information concern

the occurrence of subsequent cardiac events. The near-IR
signature of sites or lesions that eventually progress to an
event may be considered the near-IR sign or indicator of

plaque vulnerability. This relationship may be used to con
struct a near-IR index of true vulnerability of coronary

plaques in living patients. Various embodiments of the
invention make this particularly feasible in that near-IR
45

spectroscopy may identify plaques With a lipid pool and thin
cap in vivo, and may be performed through a coronary
catheter as described herein. Avalidated, prospective, near
IR index of vulnerability may be thus developed in accor

ing sPLA2 may provide neW therapeutic opportunities such

dance With the invention. Effective stabiliZation therapy may
be identi?ed thereafter, and may be Widely used in the

as the development of a speci?c inhibitor of the isoform of
the enZyme located in macrophages. The development of a

treatment of high-risk patients undergoing coronary inter

loW-risk method to identify vulnerable plaques in high-risk

ventions. Collagen degradation by MMPs and plaque

patients undergoing PTCA/stenting Would greatly aid in the
conduct of studies to diminish that risk With speci?c drug
therapy. Individuals at increased risk of disruption of a
vulnerable plaque may be assisted by the invention Which
creates the foundation for the development of interventions

such as 600 or more undergoing angioplasty Wherein three
major coronary arteries are scanned for the presence of
vulnerable plaques as described herein. There may be

folloW-up procedures for up to several years to determine

further elucidated by the invention, and Will be measured in
tance of sPLA2 as a determinant of plaque vulnerability may

(MMPI), and, possibly, an inhibitor of Group v secretory
phospholipase 2 (sPLA2). Patients may also be selected for
intensive lipid loWering therapies if they Were found to have

in?ammation have been demonstrated in atherosclerotic

that prevent the sudden onset of a catastrophic coronary

tissue, and Well-tolerated, orally active inhibitors are also
available. Studies of plaque stabiliZation in such patients
may further yield information of great value for all indi
viduals at risk of plaque disruption and coronary events.
Additional objects and advantages of the invention Will

event.

become apparent to those skilled in the art upon examination
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It is another object of the invention to provide near-IR

of the foregoing description of the invention Which may be
modi?ed Without departing from the scope of the invention.

imaging of plaque composition and vulnerability in vivo.
Near-IR spectroscopy may identify vulnerable lesions in the

coronary arteries of living patients. In particular, vulnerable
coronary plaque may be detected because of the unique

advantages provided by the catheter-based near-IR imaging
systems described herein despite the general dif?culty in
imaging coronary lesions. These catheter-based near-IR
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BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 provides an illustration of the near-IR spectrum for
cholesterol.
FIG. 2 provides an illustration of the near-IR spectrum for

lysophosphatidylcholine (LPC).
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FIG. 3 provides an illustration of the near-IR spectrum for
a ?brous cap associated With vulnerable plaques.
FIG. 4 illustrates the spectrum for rat aortas through
Whole blood and saline.
FIG. 5 illustrates the spectrum for polystyrene through a

particularly in coronary circulation, that may be readily
implemented as part of an early detection and intervention
program.

A. Prospective Identi?cation of the Vulnerable Plaque
In general, a plaque that is formed With a large lipid pool,

rat aorta.

a thin ?brous cap and macrophage in?ltration, is a plaque

FIG. 6 is an illustration of a near-IR catheter used in vivo
shoWn While illuminated With a HeNe laser Where light can

that may be considered vulnerable to disruption (Muller J E,
Kaufmann P G, Luepker R V, Weisfeldt M L, DeedWania P
C, Willerson J T, Mechanisms precipitating acute cardiac

be seen returning doWn a receiving optical ?ber from the
catheter tip When the catheter is held against an optical table.

events: RevieW and recommendations of an NHLBI

Workshop, National Heart, Lung, and Blood Institute:

FIG. 7 illustrates a catheter laid beside the heart and aorta

Mechanisms Precipitating Acute Cardiac Events

of a rabbit, and a meter stick Wherein a suture is tied on the

Participants, Circulation 1997; 96(9):3233—9 (cited refer

catheter at the point of maximum insertion to enable the

ences are incorporated herein by reference)). While lipid and
macrophage-laden plaques are vulnerable to disruption, it is
important to recogniZe the incomplete nature of the basis for

penetration to the aortic arch to be determined by measuring
the distance betWeen the suture and the femoral artery at
each location Where spectra may be obtained.
FIG. 8 shoWs the average near-IR spectra from a 1-cm

supporting this hypothesis. Although large lipid pools and
thin caps With macrophages have been identi?ed in dis
rupted plaques, a prospective study has not been conducted
to demonstrate that these features are predisposed to disrupt,

aorta segment of a control and a cholesterol-fed rabbit

Wherein the solid lines represent spectra of the control aorta,
and the dot-dashed lines represent the spectra of the

even in an animal model. Also, such microanatomy does not

cholesterol-treated aorta.

FIG. 9 provides a representative frame from a control
video clip Where increased LDL uptake is represented as a
darker gray color.
FIG. 10 provides a representative frame from a
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cholesterol-fed video clip Where increased LDL uptake is
represented as a darker gray color.

account for the plaques that erode and produce thrombosis.
HoWever, the concepts of the present invention are directed
to the identi?cation and characteriZation of certain lesions
(plaques With lipid pools and thin, Weakened caps, or some
other features) that are particularly vulnerable to disruption.
These types of vulnerable plaques have been detected and

identi?ed prior to disruption, in part, by folloWing the

FIG. 11 provides a data table for the identi?cation vul

patients until a suf?cient number of coronary events

nerable plaque characteristics in humans by near-IR imag

occurred (Uchida et al, Prediction of acute coronary syn

mg.

dromes by percutaneous coronary angioscopy in patients
With stable angina, Amer Heart J 1995, 130 (2): 195—203).

FIG. 12 illustrates the spectra of a lipid pool and ?brous
cap associated With human vulnerable plaque.

The events occurred With greater frequency at sites sus
pected to be vulnerable than at non-vulnerable sites. Given

FIG. 13 is a simpli?ed representation of one embodiment

of the apparatus provided by the invention that includes a
compound parabolic concentrator for the analysis of tissue.

35

the present state of knoWledge, and for purposes of avoiding
confusion herein, the term vulnerable may describe the
pathologic ?ndings of a plaque having a large lipid pool, a
thin cap, and an in?ammatory in?ltrate (Muller J E, Abela G
S, Nesto R W, To?er G H, Triggers, acute risk factors and

40

vulnerable plaques: The leXicon of a neW frontier, J Am Coll

FIG. 14 is a simpli?ed representation of another embodi
ment of the invention that includes an inverted, substantially

cone-shaped re?ector.
FIG. 15 is a distal end vieW of a ?ber-optic bundle used

in apparatus provided by the present invention.
DETAILED DESCRIPTION OF THE
INVENTION

The present invention provides methods and apparatus for
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in vivo detection and characteriZation of vulnerable athero

sclerotic plaques With near-infrared (IR) spectroscopy. Each
of the disclosed embodiments may be considered individu
ally or in combination With other variations and aspects of

the invention. The near-IR spectrometric imaging tech
niques described herein may be used to non-destructively

Cardiol 1994; 23:809—13). Vulnerable may also refer to
plaques that may be identi?ed in the future With near-IR
imaging in accordance With the invention that also lead to a
higher rate of events. A subset of plaques shoWn to be
vulnerable by near-IR With supporting outcome data may be
further characteriZed as vulnerable plaques as de?ned by
histology. In any event, the identi?cation of vulnerable
plaques prior to disruption as described herein provides an
enormous advantage in the prevention of cardiovascular
disease, and further provides an opportunity to effect appro
priate treatment Which Would convert such plaques to non

vulnerable plaques.
B. Near-IR Imaging For Identifying Vulnerable Coronary

locate and identify loW-density lipoprotein (LDL) choles
terol Which may serve as an in vivo marker for the presence

Plaques

of vulnerable atherosclerotic plaques. Vulnerable plaques
or Without a triggering activity or event of a patient, to

The invention provides methods and apparatus to identify
vulnerable coronary plaques in patients With near-IR spec

events such as ulceration, rupture, erosion leading to throm
bosis causing an acute syndrome. The characteriZation and
risk assessment of clinical patients using near-IR laser

light in the near-IR spectrum, in a speci?c manner, by
organic molecules. This creates unique re?ectance spectra

may be generally described as plaques that are prone, With
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trometry. These techniques are based on the absorbance of

spectrometric assays of vulnerable plaque in vivo may
enable the assignment of patients to speci?c drug or surgical

that can be used to obtain a chemical analysis of tissue in a
non-destructive manner.

1. Features of Near-infrared Spectrometry.
The near-IR region of the electromagnetic spectrum, once

interventions selected to match individual plaque character
istics.
I. Applications for in vivo Identi?cation and CharacteriZa

tion of Vulnerable Plaque
The invention provides methods and apparatus for the
identi?cation and characteriZation of vulnerable plaques,

regarded as having little potential for analytical Work, has
65

become one of the most promising for molecular spectrom

etry. The advent of inexpensive and poWerful computers has
further contributed to the surge of neW near-IR spectrometric

US 6,816,743 B2
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applications. The near-IR region is usually estimated to

chemical analyses With a single near-IR spectral scan. The
near-IR spectrum of a sample, Which is generated from
combinations and harmonics of fundamental molecular
motions, contains more chemically speci?c information than
is ordinarily available in an ultrasonic absorbance spectrum.
At the same time, the large number of near-IR

include Wavelengths betWeen 700 nm (near the red end of
the visible spectrum) and 3000 nm (near the beginning of

infrared stretches of organic compounds). Absorbance peaks
in the near-IR region originate from overtones, from com
binations of the fundamental (mid-IR) bands and from
electronic transitions in the heaviest atoms. For example,
C—H, N—H, and O—H bonds are responsible for most

major absorbance peaks observed in the near-IR spectrum,
and near-IR spectrometry is used chie?y for identifying or
quantifying molecules that contain unique hydrogen atoms.
Near-IR spectrometry is therefore used routinely for quan
titative analyses of Water, alcohols, amines, and any com
pounds comprising C—H, N—H, and/or O—H groups. It
has been also used industrially for a number of years to
determine the sites and amount of saturation in unsaturated

fatty acid esters (WetZel D, Near-infrared re?ectance analy
sis: Sleeper among spectroscopic techniques, Anal Chem
1983; 1165A—76A). In addition, near-IR spectrometry is
characteriZed by loW molar absorptivities and light scatter

chromophores, and the intrinsically high signal-to-noise
ratio (S/N) of near-IR instruments, give near-IR spectrom
etry improved sensitivity to lipids and collagens in samples
10

such as vulnerable coronary artery plaques, as described

herein, than is available through MRI. Near-infrared spec
trometry has been used to identify thousands of chemicals,
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including such biologically interesting analytes as
cholesterol, HDL, and LDL (Cassis L A, Lodder R A,
Near-IR imaging of atheromas in living arterial tissue,

Analytical Chem. 1993; 65(9):1247—56), glucose and albu
min (Drennen J K, Gebhart B D, Kraemer E G, Lodder R A,

Near-infrared spectrometric determination of hydrogen ion,
glucose, and human serum albumin in a simulated biological
20

matrix, Spectroscopy 1990; 28—36).

ing Which permit conservation of time and materials in
comparison to more conventional analytical methods
because of various reasons including: 1) analysis times

b) Identi?cation of Spectral Difference BetWeen Different
Types of Complex Tissues

under one second are possible; 2) simultaneous multi

ment of cerebral oxyhemoglobin and deoxyhemoglobin in
adults (ElWell C E, Matcher S J, TysZcZuk L, Meek J H,

component analysis is the norm; 3) no sample preparation is
usually required for liquids, solids, or gases; 4) non-invasive
and non-destructive analysis is possible; 5) the cost-per
analysis is very loW (no reagents are used); 6) physical

Near-infrared spectrometry has been used for measure
25

Delpy D T, Measurement of cerebral venous saturation in
adults using near infrared spectroscopy, Adv Exp Med Biol

1997; 411:453—60). Non-invasive near-IR spectrophotom

properties and biological effects can be calculated from

spectra of samples; 7) automated correction of background

30

and interferences is performed in instruments using com

puter algorithms; 8) detection limits can be very loW; 9)
samples siZes ranging “from picograms to planets” can be
analyZed; and 10) molecular structural information can be
derived from spectra.
2. Technical Aspects of Near-IR Imaging

J M, Landrum W, Mayes L, Zou Y, Lodder R A, Near-IR
35

(?lter Wheel, monochromator, interferometer or laser) exter

an indium antimonide focal plane array video camera.
40

for spectrometry, or may be detector arrays in cameras for

calibration, nv=29 patient plaques for cross validation). The
data Were normaliZed by Z-scoring, so a ?at line at y-axis=0
45

spectrometry had been plagued historically by problems
With high Water absorbance in tissue, light scattering, peak
overlap, and peak shifting With temperature and sample
matrix composition. HoWever, more intense and more stable
light sources, more ef?cient detectors (and in many cases,

Inverse principal axis transformation revealed the linear
combination of lipoproteins that correlated to necrosis in the

plaque pathology reports (nc=29 patient plaques for

spectrometric imaging. Modem near-IR spectrometers and
sampling techniques have improved to the point that it is
possible to analyZe intact ?nished pharmaceutical products,
and even analytes in living human patients. In vivo near-IR

spectrophotometric monitoring of stroke-related changes in
the protein and lipid composition of Whole gerbil brains,
Anal Chem 1993; 1305—13). It has been also used transar
terially in the carotid arteries of human patients to identify
?brous caps, lipids, thrombus, ulceration and necrosis With

Near-IR spectrometry typically uses a tunable light source

nal to the experimental subject to determine the chemical
composition of a sample. Detectors can be single elements

etry of gerbil brain tissue in vivo has been shoWn to
discriminate betWeen adult (three to four months of age) and
aged (18 to 20 months of age) brains, as Well as betWeen
brains exposed to ?ve and ten minutes of ischemia (Carney

represented the average gel appearance. Positive deviations
from y=0 represented more protein in the molecular mass

region than the average gel, While negative deviations rep
50

resent less protein in the molecular mass region than the
average gel. Amaj or difference betWeen the necrotic plaques
and the plaques Without necrosis is the presence of a 128 KD

obtaining rapid Wavelength selectivity have permitted appli

lipoprotein in the necrotic plaques.
4. Potential Advantages of Near-IR for Identifying Vul

cation of near-IR imaging to increasingly complex biologi

nerable Coronary Plaques

more ef?cient imaging detectors), and improved methods of
cal and medical problems. The importance of these instru
mental advances is evident in the application of near-IR
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strate effective chemical sensitivity and speci?city. As
described above, a major advantage of near-IR spectrometric

spectrometry to atherosclerosis and stroke research. Using a
specially modi?ed IR video camera, different band pass
?lters or tunable lasers permit collection of image spectra
over the range of 1000—4000 nm (near-IR and IR spectral

range) (Dempsey R J, Davis D G, Buice R G, Lodder R A,
Biological and medical applications of near-infrared

The methods and apparatus provided herein for identify
ing and characteriZing vulnerable coronary plaques demon
imaging over ultrasonic and MRI is its ability to perform
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simultaneous multi-component chemical analyses using a
single near-IR spectral scan. Moreover, near-IR spectrom

spectrometry, Appl Spectrosc 1996; 18A—34A).

etry can be implemented in a catheter as described herein
Which are even smaller than those devices used in ICUS, and

3. Methods of UtiliZing Near-IR Imaging

permit high resolution (both spatial and chemical) analyses

a) Identi?cation of speci?c compounds
A major advantage of using near-IR spectrometric imag
ing over ultrasonic and magnetic resonance imaging (MRI)

is its ability to perform simultaneous, multi-component

to be performed Within arterial vessels of living patients. The
65

cost of catheters described herein may be relatively loW

enough to make them disposable, single-use devices. The
high intensity and tunability of external cavity tunable diode
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lasers also makes intravascular near-IR imaging a durable

cells (Friedman M, The coronary thrombus: Its origin and
fate, Hum Pathol 1971; 2:81—128). The release of pro
teolytic enZymes, in particular MMPs, by these cells has

and relatively inexpensive solution. The rapidity of high S/N
spectral data collection further enables complete chemical

been suggested as a mechanism leading to plaque vulner

maps of blood vessels like coronary arteries to be readily
obtained during an interventional PTCA. The invention thus
provides an accurate non-destructive in vivo reference assay

for most lipids and proteins immobilized in the Walls of
living human arteries. In addition to detecting vulnerable
plaque, chemical analysis of lesions in vivo may be accom
plished Which may further the kinetic study of atherogenesis
and contribute to the understanding of lesion formation and
groWth. The methods and apparatus described herein may
play key roles in the monitoring the progression or regres
sion of, the vulnerability of lesions. Near-IR spectrometry of
plaque in vivo may facilitate assignment of patients and
plaques to speci?c neW drug interventions that affect the

ability and rupture (Richardson P D, Davies M J, Born G V,
In?uence of plaque con?guration and stress distribution in
?ssuring of coronary atherosclerotic plaques, Lancet 1989;
2:941—4; Davies M J, Richardson P D, Woolf N, KatZ D R,
Mann J, Risk of thrombosis in human atherosclerotic

plaques: Role of extracellular lipid, macrophage and smooth
muscle content, Br Heart J 1993; 69:377—81; Seppo T, Kevin
D, Marina F et al, Interstitial collagenase expression in
human carotid atherosclerosis, Circulation 1995;

92:1393—8; Zorina G, Galina S, Roger K, Stephen C, Libby
15

constitutively produce matrix-degrading proteinases, Proc
Natl Acad Sci USA 1995; 92:402—6). MMPs have also been
found to be active in spread of tumors (Stetler-Stevenson
WG, Liotta LA, Kleiner D E, Extracellular matrix 6: Role
of matrix metalloproteinases in tumor invasion and
metastasis, FASEB J 1993; 7:1434—41; BroWn P, GiavaZZi
R, Matrix Metalloproteinase inhibition: A revieW of anti
tumour activity, Annal of Onc 1995; 6:967—74) and other
conditions such as rheumatoid arthritis (Yoshihara Y, Obata

course of atherosclerosis. Better treatment programs may be

thus designed that focus on these mechanisms.
C. Clinical Issues

1. Prognosis of Post-PTCA/Stenting
The near-IR imaging described herein may be performed

on patients undergoing PTCA/stenting Who Will already
have a Wire inserted in a culprit artery for clinical reasons.

Arationale for near-IR imaging in these patients may be that

during the folloWing year folloWing PTCA/stenting,
approximately 10% Will experience death, myocardial inf
arction (MI), or require repeat revasculariZation because of
rapid progression of a plaque other than the one originally
treated. It is the progression of such plaques that has
substantially led to the inability of PTCA/stenting and
CABG to prevent subsequent MI in randomiZed studies.
2. Therapy to Stabilize Vulnerable Plaques
Different therapies have been developed thus far for
stabiliZing vulnerable plaques. These and future treatments
may be carried out in light of the bene?ts conferred by the

25

K, Fujimoto N, Yamashita K, HayakaWa T, Shimmei M,
Increased levels of stromelysin-1 and tissue inhibitor of
metalloproteinases-1 in sera from patients With rheumatoid

arthritis, Arthritis Rheum 1995; 38:969—75), osteoarthritis
(Manicourt D H, Fujimoto N, Obata K, Thonar E J, Serum
levels of collagenase, stromelysin-1, and TIMP-1, Age and
sex related differences in normal subjects and relationship to
the extent of Joint involvement and serum levels of antigenic
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invention as described herein.

a) Lipid Lowering
In contrast to the experience With revasculariZation,
intense lipid loWering With statins has been found to prevent
MI. The observation that the degree of prevention of MI
exceeded the modest improvements in ?xed stenoses, has
led to some speculation that the therapy stabiliZed vulner
able plaques. While this may occur, even When lipid loW
ering therapy is administered maximally, the event rate for
this group remains high, and additional therapies are still

P, Macrophage foam cells from experimental atheroma

keratin sulfate in patients With osteoarthritis, Arthritis
Rheum 1994; 37: 1774-83), liver cirrhosis (Takahara T, Furui
K, Funaki J et al, Increased expression of matrix
metalloproteinase-II in experimental liver ?brosis in rats,

Hepatology 1995; 21:787—95), Crohn’s disease and emphy
sema (Shapiro S D, Elastolytic metalloproteinases produced
40

by human mononuclear phagocytes, Potential roles in
destructive lung disease, Am J Respir Crit Care Med 1994;

150:S160—S164).
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generally needed.

Activity of MMPs in tissue is regulated at many levels.
Initially, their expression is modulated at the gene level, and
moreover, they are secreted in proenZyme form and require
activation. Further modulation is primarily achieved by a
balance betWeen enZyme concentration/activity and nonspe

b) Matrix Metalloproteinases

ci?c (2-macroglobulin) and speci?c (tissue inhibitors of

Matrix metalloproteinases (MMPs) are a group of pro

metalloproteinases -TIMPS) inhibitors. In addition to natu
rally occurring inhibitors, a number of designed inhibitors
have been developed, and are in different phases of testing
for their investigational and clinical utility. Most of the

teolytic enZymes that can digest collagen and elastin in the
extracellular matrix. Several studies have identi?ed MMPs
in animal and human vulnerable plaques. The MMPs Within
plaques are believed to be secreted by activated macroph

ages (Matrisian L M, The matrix degrading
metalloproteinases, Bioessays 1992; 14:455—63) and to be at
least in part responsible for extracellular matrix degradation
leading to Weakening of plaques ?brous cap, and plaque
rupture With its clinical sequelae (Henney A M, Wakeley P

human studies to date are at the stage of phase I/II clinical

trials. The safety pro?le of synthetic MMPs inhibitors in
therapy of prostate, lung, colon and breast malignancies is
55

satisfactory. Agouron Pharmaceuticals Inc., for example, has
designed and produced several MMP inhibitors (MMPI).
One inhibitor has thus far demonstrated relatively poWerful

R, Davies M J et al, LocaliZation of stromelysin gene

activity against stromelysin, and has been quite Well toler

expression in atherosclerotic plaques by in situ
hybridiZation, Proc Natl Acad Sci USA 1991; 88:8154—8).

ated in over 150 patients With prostate cancer. At the present
time, there are no knoWn published studies relating to the
use of natural or synthetic MMPIs to inhibit plaque disrup
tion and/or accelerate transition to mature, stable, dormant

Thickness and collagen content of the ?brous cap are

important for the stability of the plaque (Loree H M, Kamm

plaque. HoWever, in experimental ex vivo models involving
human atherosclerotic plaques and activated macrophages,

R D, StringfelloW R G, Lee R T, Effects of ?brous cap
thickness on peak circumferential stress in model athero

sclerotic vessels. Circ Res 1992, 71, 850—858). The plaque
disruption occurs most frequently at sites Where the ?brous
cap is the thinnest and the most heavily in?ltrated by foam
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MMP inhibitors have been shoWn to substantially decrease
extracellular matrix degradation. In summary, MMPs may

be indeed involved in plaque vulnerability, and Well

US 6,816,743 B2
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tolerated inhibitors are presently available for human studies
Which may be used in accordance With the principles of the
invention.

troscopy Within blood vessel Walls as shoWn in FIG. 4

(Cassis LA, Lodder R A, Near-IR imaging of atheromas in

living arterial tissue, Analytical Chem. 1993; 65(9)

c) sPLA2 inhibitors

:1247—56). Fiber-optic probes and a monochromator system

While the role of sPLA2 in vulnerability has not received
as much attention as MMPs, this enZyme and the products

With a 1000 W tungsten-halogen lamp Was used to obtain
spectra of the aortas of rats. The natural reduction in

it creates, may play a role in weakening plaque, perhaps at
a more basic level. Further research may clarify its role, and
if it is active, inhibitors for clinical use may be also obtained
and used in combination With other aspects of the invention.

D. Early Detection and Characterization of Vulnerable

scattering of light in this long Wavelength region and the
reduced absorbance of Water in this Water WindoW, com

bined to permit the collection of good-quality spectra In
10

Although the procedures and apparatus provided herein

through both Whole blood and phosphate-buffered saline

may detect vulnerable coronary plaques to help identify
groups at higher risk, most individuals actually experience
their ?rst MI and/or a coronary death prior to their ?rst

15

catheteriZation. Signi?cant bene?ts may be still achieved
nonetheless if the invention Were directed to a sample subset

of 400,000 patients Who undergo PTCA/stenting. The treat

(PBS) as demonstrated in FIG. 4, and are shoWn With solid
and dashed lines. The spectra are virtually identical and
overlap over most of the Wavelength range examined.
In a further test of the penetration ability of near-IR light,
the spectrum of a polystyrene Wavelength-calibration stan
dard may be obtained through a rat aorta as shoWn in FIG.

ment for this group of the population may lead to less
invasive means of detection and treatment that are appli

general, the ?ber-optic probe may be operated relatively
close to the vessel Wall (<1 mm) to minimiZe interference
from Whole blood. Spectra of the aorta may be obtained

Plaque

20

5 (Cassis LA, Lodder R A, Near-IR imaging of atheromas

cable to the much larger group of individuals With knoWn
coronary artery disease (CAD), or are at high risk for CAD.

in living arterial tissue, Analytical Chem. 1993; 65(9)

In accordance With the principles of the present invention,
near-IR mapping may be performed With these patients Who
may undergo diagnostic catheteriZation for purposes of

trans-arterially by transmitting the light from a ?ber-optic

:1247—5 6). The spectrum of the polystyrene may be obtained
25

comparison to established a near-IR vulnerability index. The

probe placed on the outside of the aorta, through both Walls
of the aorta, then through the polystyrene, re?ected back off
a mirror, and back through the polystyrene and both Walls of

procedure may be highly predictive of subsequent events,

the aorta to the detector. The total path length Was 4 mm,

and may offer safe and ef?cacious treatment for identi?ed

Which is generally deeper than a human coronary plaque.
FIG. 5, depicts three spectra: the loWest (the spectrum of the

plaque vulnerability in subsequent cases.
II. Preliminary Studies and Discussion
The folloWing section is a description of near-IR imaging

30

less spectrum is the spectrum of the aorta), and the upper

spectrum (the spectrum of the polystyrene obtained through
the aorta). The spectral absorbance peaks of polystyrene

studies in laboratory settings that included various applica
tions for the methods and apparatus provided in accordance
With the principles of the invention.
A. Near-IR Spectrometry
1. Near-IR Analytes Measured In vitro

The invention incorporates technology relating to near-IR
of analytes measured in vitro including quantitative and
qualitative near-IR spectrometry of cholesterol, cholesterol
esters, cholesterol monohydrate, and lipoprotein cholesterol
in blood serum and in plaques (Cassis LA, Yates J, Symons
W C, Lodder R A, Cardiovascular near-infrared imaging, J
Near-Infrared Spectrosc 1998; Lodder R A, Moorehead W,
Robertson S P, Rand PHGM, Assessment of the Feasibility
for Determination of Cholesterol and Other Blood Constitu

shoW through Well in the 1100—1300 nm and 1600—1850 nm
35

although they may be greatly diminished by the large
background absorbance of Water.
3. Imaging the Rabbit Aorta Through a Catheter
40

arterial thrombosis production by systemic procedures, Arch
45

disruption and arterial thrombosis in an atherosclerotic rab

50

feature of the model (not the triggering aspect) Was used to
test the near-IR catheters provided herein. In the imaging of
rabbit aortas, a NdzYAG-pumped KTP/OPO laser system
Was used to test experimental spectrometric catheters devel

oped for use in several projects investigating atherosclerosis
and markers of vulnerable plaque. The purpose of this

With the fourth poWer of Wavelength, and because this
55

experiment Was to test the hypothesis that a near-IR spec
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trometric catheter is capable of early detection of cholesterol
uptake in the arterial Wall through Whole blood even before
the appearance of visible fatty streaks. The light source used
in the catheter experiments Was a laser system consisting of
a MIRAGE 3000B Mid-Infrared Optical Parametric Gen
erator and a Continuum NY81—10 NdzYAG Pump Laser.
The system provides tunable near-IR light With a Wave
length from 1.4 to 4.1 micrometers and an effective poWer

presence of ?brous caps on vulnerable plaques, and to
determine the siZe of the cap With near-infrared imaging as
shoWn in FIG. 3.

2. Near-IR Imaging through Whole Blood
Near-IR light in the 1600—1900 nm Wavelength region
penetrates suf?ciently through Whole blood to enable spec

Pathol 1961; 72:197—208). This rabbit model develops vul
nerable plaques prone to rupture With subsequent thrombosis
(Abela G S, Picon P D, Friedl S E et al, Triggering of plaque

bit model, Circ 1995; 91:776—84). The plaque generation

1. These absorbance-Wavelength features may be used to

near-IR spectrum that can be used to detect the activity of
sPLA2 in in?ammatory processes. The near-infrared diffuse
re?ectance spectrum of collagens may be used to detect the

Some of the studies described herein Were conducted

using the atherosclerotic rabbit model introduced by Con
stantinides et al. (Constantinides P, Chakravarti R N, Rabbit

identify and quantify cholesterol simultaneously With other
components in mixtures. Because light scattering decreases
spectral region is far removed from the hemoglobin elec
tronic absorbance that lies beloW 1000 nm, light penetration
through Whole blood is typically very good. As shoWn in
FIG. 2, lysophosphatidylcholine (LPC) also has a unique

Wavelength regions. The largest peaks of polystyrene (the
triplet at 2140—2200 nm) may even shoW through someWhat.

ents by Near-Infrared Re?ectance Analysis, Talanta 1989;
36:193—8). The spectrum of cholesterol has unique identi
fying features in a so-called Water WindoW Where Water has
minimal absorbance (i.e., no vibrational energy absorbance
peaks) betWeen about 1450 and 1950 nm as shoWn in FIG.

polystyrene standard alone), the middle (someWhat feature
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of 3.3 million Watts. The spectra Were scanned in the Water
WindoW betWeen 1650 and 1780 nm, Where LDL cholesterol

is generally knoWn to have tWo major peaks. The catheters
Were constructed in-house from communications-grade opti

